2015 Fiscal Year Final Research Report
Study of prognostic biomarker KLF4 and Her4 for triple negative breast cancer
| Project/Area Number |
25461975
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | University of Toyama |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TSUKADA Kazuhiro 富山大学, 大学院医学薬学研究部(医学), 教授 (90171967)
SHIMADA Yutaka 富山大学, 大学院医学薬学研究部(医学), 准教授 (30216072)
OZAWA Tatsuhiko 富山大学, 大学院医学薬学研究部(免疫学), 助教 (10432105)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Keywords | TNBC / CTC / KLF4 / siRNA / EMT / OS / DFS |
|---|
| Outline of Final Research Achievements |
We assessed the expression levels of KLF4 in 84 patients with TNBC by immunohistochemical staining. In addition, CTCs in the peripheral blood of TNBC patients were identified and compared with primary lesions in terms of KLF4 expression. Moreover, the expression of KLF4 was inhibited by transfecting cultured TNBC cells with the siRNA of KLF4 to analyze the effects of KLF4 on cell proliferation and EMT-like changes.
In the 84 patients with TNBC, higher KLF4 expression was associated with significantly better OS and DFS. KLF4 expression was lower in CTCs than in cancer cells in TNBC primary lesions. TNBC cells with inhibited KLF4 expression exhibited a greater ability to growth. These cells also underwent EMT-like changes with reduced expression of epitherial factors such as E-cadherin.
TNBC patients with reduced KLF4 expression had poor outcomes. The results of our experiments suggest the expression of KLF4 is one of the important factors that inhibit the EMT and growth of TNBC.
|
| Free Research Field |
乳癌 バイオマーカー
|
